Panel Tells F.D.A. That CRISPR Sickle Cell Cure Is Safe Enough for Patients

Panel Tells F.D.A. That CRISPR Sickle Cell Cure Is Safe Enough for Patients

The New York Times - Business:

The decision by an advisory committee may lead to Food and Drug Administration approval of the first treatment for humans that uses the CRISPR gene-editing system.

This post first appeared in The New York Times - Business. Read the original article.